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induced vascular endothelial mesenchymal transition (EndMT) can occur during the development of RIPF. Here, we exam-
ined the direct contribution of endothelial HIF-1a (EC-HIF1a) on RIPF.
Methods and Materials: An inducible Cre-lox-mediated endothelial Hif1a deletion mouse line was used to evaluate the po-
tential of HIF-1a inhibition to suppress RIPF. To evaluate the effects of a pharmacologic HIF-1a inhibitor on RIPF after im-
age guided radiation therapy (IGRT) for spontaneous lung adenocarcinoma, we generated conditional tdTomato; K-RasG12D;
and p53 flox/flox mice to facilitate tracking of tumor cells expressing tdTomato.
Results: We found that vascular endothelial-specific HIF-1a deletion shortly before radiation therapy inhibited the progres-
sion of RIPF along with reduced EndMT, whereas prolonged deletion of endothelial HIF-1a before irradiation did not. More-
over, we revealed that postirradiation treatment with the novel HIF-1a inhibitor, 2-methoxyestradiol (2-ME) could efficiently
inhibit RIPF and EndMT. In addition, IGRT using primary mouse models of non-small cell lung cancer showed that com-
bined treatment of 2-ME with ablative high-dose radiation therapy efficiently inhibited RIPF and the growth of both multi-
focal and single tumors, concomitantly reducing radiation-induced EndMT of normal as well as tumor regions.Corresponding author: Yoon-Jin Lee, PhD; E-mail: yjlee8@kirams.re.kr
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More than 70% of patients with thoracic cancer receive
radiation therapy (RT).1-3 During radiation therapy,
radiation-induced lung injury (RILI), such as pneumonitis
and fibrosis, can cause morbidity such as scarring of lung
tissue and breathing difficulties, and is therefore considered
as a treatment-limiting factor. In particular, 13% to 37% of
patients with lung cancer, who receive RT, are susceptible
to the development of radiation pneumonitis or fibrosis in
the early or late phase of treatment, respectively.4,5
Although recent improvements to radiation treatment mo-
dalities, such as stereotactic body radiation therapy
(SBRT), have minimized the extent of targeted tissue and
therefore the risks to nontargeted tissue, radiation-induced
pneumonitis and fibrosis remain the most common toxic-
ities associated with SBRT of lung cancer.6,7 However,
despite numerous studies, little progress has been made to
reduce RILI; the medications developed for its reduction
including steroids, ACE inhibitors, and pentoxifylline8 have
shown limited efficacy.
As an alternative, relevant animal models have been
used to study radiation-induced lung fibrosis (RIPF) in
cancer therapy and its amelioration using medications.
In vivo RIPF studies have been performed mainly in the
thoracic-irradiated normal lung.9,10 An experimental RIPF
model using focal ablative RT with high-dose irradiation
can simulate clinical stereotactic radiation therapy
(SBRT).11,12 Specifically, delivering a single dose of 75 or
90 Gy irradiation to the left lung of mice caused inflam-
mation and prefibrotic or fibrotic damage at 2 weeks
postirradiation.12,13 Moreover, to evaluate the efficacy of
RT for cancer, human tumor features have been considered
using genetically engineered mouse models (GEMM).14
Unlike transplanted tumor models, RIPF studies using
GEMMs may recapitulate the immune system and other
normal tissues in the microenvironment around tumors.
Therefore, a preclinical RIPF animal model of image
guided RT (IGRT) for a GEMM-based single lung tumor or
multifocal tumors may be useful as a preclinical platform.
The endothelial cell-to-mesenchymal transition
(EndMT) can predominantly be observed in radiation-
induced normal tissue damage.12,15,16 EndMT is a phe-
nomenon characterized by the loss of cellecell junctions
and acquisition of invasive and mesenchymal phenotypes,
for example, in the process of cardiac and liver fibrosis.17,18
Mesenchymal markers (eg, alpha-SMA, FSP-1, and
vimentin) are upregulated, whereas endothelial cell (EC)e
specific adhesion markers (eg, CD31 and VE-cadherin) are
downregulated in the EndMT process. Hypoxia-inducedvascular EndMT occurs during RIPF and is dependent on
the hypoxia inducible factor 1 alpha (HIF-1a) expression of
vascular ECs in human irradiated lung tissues.12 The tumor
vascular EndMT predominantly appears in tumor regrowth
after radiation therapy for non-small cell lung cancer
(NSCLC), and modulation of EndMT inhibits tumor
regrowth, ultimately affecting tumor immunity and cancer
stem cell proliferation.19 Thus, negatively regulating
vascular EndMT may enhance the efficacy of radiation
therapy, thereby inhibiting tumor regrowth and RIPF. One
anticancer drug, 2-methoxyestradiol (2-ME), approved by
the US Food and Drug Administration (FDA) and suc-
cessfully used in clinical treatment for breast, prostate, and
ovarian cancer,20,21 can function as an HIF-1a inhibi-
tor22,23; it also inhibits radiation-induced EndMT by
reducing HIF1 expression in human umbilical vein endo-
thelial cells (HUVECs) and limits RIPF after 16 Gy
thoracic irradiation in vivo.12
In the present study, we examined the direct contribution
of endothelial HIF-1a (EC-HIF1a) in RIPF using a GEMM
to affect tamoxifen-inducible CreERT2-mediated EC-Hif1a
deletion in addition to the effect of 2-ME administration.
Deleting EC-Hif1a shortly before focal irradiation signifi-
cantly inhibited vascular EndMT and subsequent RIPF
development, whereas these benefits were not observed at
prolonged deletion before radiation therapy. Consistently,
2-ME treatment after but not considerably before ablative
high-dose radiation therapy inhibited RIPF and reduced
EndMT. Furthermore, evaluation of the effects of 2-ME on
RIPF after IGRT for spontaneous lung adenocarcinoma in
conditional KrasG12D;Trp53flox/flox mice revealed an in-
crease in tumor radiosensitivity. Together, these findings
suggest that targeting EC-HIF1a with 2-ME might consti-
tute a therapeutic strategy to increase the efficacy of radi-
ation therapy by negatively regulating radiation-induced
EndMT.Methods and Materials
Study design
The goals of this study were to demonstrate the role of
vascular endothelial HIF-1a as a regulator of radiation-
induced EndMT, on RIPF and to suggest a promising in-
hibitor of RIPF. We used genetically engineered mice to
define the role of endothelial HIF-1a and observed histol-
ogy and immunofluorescence images. Temporal HIF-1a
deletion was performed using a tamoxifen-inducible gene
deletion system. Thoracic radiation dose and volume were
selected based on a previous study. Fibrosis was quantified
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staining and the collagen deposition in Masson trichrome
staining. EndMT was quantified by SMAþCD31þ endo-
thelial area of immunofluorescence. To perform IGRT for
spontaneous tumors, we estimated tumor formation using
IVIS every week. When a single tumor size was 100 to 150
mm3, IGRT was performed. All animal experiments were
approved by the Institutional Animal Care and Use Com-
mittee of the Korea Institute of Radiologic & Medical
Sciences and are reported in accordance with the Animal
Research: Reporting of In Vivo Experiments (ARRIVE)
guidelines.24 All studies were performed in triplicate.
Histologic quantification was performed in a double-blind
manner.
Mice
Specific pathogen-free Cdh5-CreERT2 mice were pur-
chased from Taconic Biosciences (Rensselaer, NY),
whereas specific pathogen-free C57BL/6 Tie2-Cre,
HIF1aflox/flox, Trp53flox/flox, LSL-KrasG12D, and CAG-
tdTomato mice were purchased from Jackson Laboratory
(Bar Harbor, ME). Cdh5-CreERT2;HIF1aþ/þ, Cdh5-
CreERT2e/e, or Tie2-Cree/e littermates were used as
controls. C57BL/6 mice were purchased from Orient Bio
Inc (Seongnam, South Korea). All animal experimental
data shown are representative of 3 independent experi-
ments. All experiments were conducted with 7- to 8-week-
old mice. Mice had ad libitum access to standard diet and
water. All mice were anesthetized with a combination of
anesthetics before being sacrificed.
Radiation-induced fibrosis model
Radiation was delivered using the X-RAD 320 platform
(Precision X-ray, North Branford, CT) as previously
described.25 The left main bronchi of 7- to 8-week-old mice
were irradiated at 90 Gy using a 3-mm diameter field to
mimic an ablative dose. Cdh5-CreERT2;Hif1afl/fl mice
were injected intraperitoneally with 1 mg of tamoxifen
(Sigma, St Louis, MO; dissolved in corn oil) once daily for
5 days starting 2 or 11 days before irradiation. C57BL/6
mice were treated with 2-ME (30, 60 mg/kg, intraperito-
neally; 60 mg/kg, by mouth), amifostine (30 mg/kg, intra-
peritoneally), or pirfenidone (30 mg/kg, intraperitoneally) 1
hour before irradiation, and dosing continued every 2 to 3
days for a total of 6 doses. In the posttreatment group,
C57BL/6 mice were treated with 2-ME (60 mg/kg, intra-
peritoneally) 4 days after irradiation, and dosing continued
every 2 days for a total of 5 doses. Further, 2-ME (Sell-
eckchem, Houston, TX), amifostine (Selleckchem), and
pirfenidone (Selleckchem) (30 mg/kg, intraperitoneally)
were dissolved in 2% (v/v) dimethylsulfoxide (DMSO) þ
30% (w/v) polyethylene glycol (PEG) 300 þ 1% (v/v)Tween 80 þ ddH2O, water, and 2% (v/v) DMSO þ 30%
(w/v) PEG 300 þ ddH2O, respectively, immediately before
injection.
Primary tumor model
LSL-KrasG12D;Trp53fl/fl mice have been described previ-
ously.14 Single nodule and multinodule lung adenocarci-
nomas were respectively induced via intrathoracic and
intranasal administration of a prepackaged Ad-Cre adeno-
virus (Cell Biolabs, San Diego, CA). After 7 weeks, mouse
thoracic regions were irradiated with 16 Gy (X-RAD 320
platform). The angiogenesis inhibitor, 2-ME, was dissolved
in DMSO and further diluted in 30% (w/v) PEG-400 so-
lution with 1% (v/v) Tween 80 immediately before intra-
peritoneal injection. The administration of 2-ME began 1
hour before irradiation, and dosing continued once daily for
10 days at 150 mg/kg (first 4 days) and 30 mg/kg (subse-
quent 6 days). Each experimental group contained 6 mice.
FDG-PET scans were performed 0, 5, 10, and 20 days after
irradiation, as previously described26 (Siemens Medical
Solutions, Munich, Germany). Mouse lung tissues were
obtained 1 and 2 months after irradiation. To evaluate
tumor progression, tumor nodules were counted in H&E-
stained lung tissue sections. For the local tumor model,
LSL-KrasG12D;Trp53fl/fl;CAG-tdTomato mice were injected
with a Cre adenovirus by inserting a needle through the
fourth left intercostal space of the posterior chest wall.
After 7 weeks, the tumoral area of the left lung in mice was
irradiated at a dose of 75 Gy using a 5-mm diameter field.
Administration of 2-ME began 1 hour before irradiation
and dosing continued every 2 to 3 days for a total of 6
doses. Micro-CT scans were performed 0, 2, and 4 weeks
after irradiation using a commercial small-animal micro-
CT scanner under general anesthesia with 2% isoflurane.
CT images were analyzed using ASIProVM software
(Concorde Microsystems, Knoxville, TN). tdTomato
immunofluorescence images were captured using an IVIS-
200 system (Xenogen, Alameda, CA) under isoflurane
anesthesia. Mouse lung tissues were obtained at 4 weeks
after irradiation.
Small animal irradiation planning and IGRT
An image guided precision irradiator (XRAD-SmART,
Precision X-ray) was used to deliver a single high dose (75
Gy) to the left lung tumor in mice. This system consisted of
an x-ray irradiation system, precision collimators for small
fields, and an image guide system using a cone beam CT
and moving stage. A single dose of 75 Gy was delivered to
the target using an opposed tangential field (Gantry angle
350 and 170) and a 5-mm collimator to protect the
opposite lung and spinal cord. SmART-plan version 1.5.0
was used for precise targeted irradiation planning. The
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Fig. 1. Endothelial specific HIF-1a deletion inhibits radiation-induced lung fibrosis and EndMT. Hif1aflox/flox (WT) and
Cdh5-CreERT2;Hif1aflox/flox (EC-HIF1aKO) mice (A) were treated with tamoxifen daily for 5 days starting at 11 (B, C) or 2
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Volume 109  Number 2  2021 HIF-1a and pulmonary fibrosis in radiation therapy 557irradiation settings were 225 kV, 13 mA, large focal size,
and Cu filter with a dose rate of 3.45 Gy/min. The pro-
cedure for dose calculation was performed as described in
the AAPM Task Group 61 Report.27Microcone beam CT (micro-CBCT)
The micro-CBCT used in this study included the parame-
ters 40 kV, 3 mA, small focal size, and an Al filter that
could be used by changing the tube voltage and x-ray tube
setting. The system used an amorphous silicon flat-panel
detector with pixel size of 200 mm (Perkin-Elmer, Wies-
baden, Germany).Histology and immunofluorescence staining
Tissues were covered with optimal cutting temperature
(OCT) compound (Sakura Finetek; VWR, IL) and snap-
frozen on dry ice or fixed in 10% (v/v) neutral-buffered
formalin, embedded in paraffin, and sectioned. The sections
were deparaffinized and stained as previously described.12
The staining procedure for the OCT sections was the
same as that for the paraffin-embedded sections, except that
antigen removal was omitted. Immunofluorescence staining
was carried out using primary antibodies against CD31
(1:200; #AF3628; R&D Systems, Minneapolis, MN),
aSMA (1:1000; #A5228; Sigma-Aldrich), Hif-1a (1:100;
#sc-53546; Santacruz), Hif-2a (1:200; #PA1-16510; Invi-
trogen), and NG2 (1:500; #AB5320; Millipore, Billerica,
MA). Fibrosis grade was determined based on the Ashcroft
score.28 Collagen deposition was assessed using Masson
trichrome staining (Polyscience). We measured collagen
deposition at the same position of irradiated lung tissues (in
the pulmonary vessel and bronchi area) for accuracy of
quantification. In case of a severe fibrotic region with no
vascular structures owing to damaged vessels, we quanti-
fied the collagen composition around alveolar tissues while
avoiding the vessel and bronchi regional area for an exact
comparison. At least 5 images per section were acquired for
quantification, and the positively stained areas were eval-
uated using Image J software. At least 5 images per section
were acquired for quantification, and positively stained
areas were evaluated using ImageJ software (NIH,
Bethesda, MD; http://imagej.net/).days (D, E) before irradiation to induce recombination, respective
after focal 90 Gy irradiation (day 10) (n Z 5-7 animals per gro
chrome staining in lung tissues, and scoring of fibrosis grade an
cation, 200). Scale bar Z 100 mm. (C, E) Immunofluorescenc
postirradiation (scale bar Z 20 mm, scale bar of cropped images
as an average of 5 fields (magnification, 100). For the Ashcrof
graphs, error bars indicate SEM. )P < .01, yP < .001, and zP
comparison). Data are representative of 3 independent experim
WT Z wild-type.Cell culture and tube formation assay
HUVECs and human pericytes were obtained from Pro-
moCell (Sungwoo Life Science, Uijeongbu, South Korea)
and cultured in Endothelial Cell Growth Medium 2 and
Pericyte Growth Medium, respectively (PromoCell) under
5% CO2. HUVECs and pericytes were used within 9 pas-
sages. Cells were irradiated with gamma rays from a 137Cs
source (Atomic Energy of Canada, Chalk River, Canada) at
3.81 Gy/min. To assess the integration of pericytes into
capillaries, HUVECs were irradiated and seeded onto
Matrigel (BD Bioscience, San Jose, CA) in the presence or
absence of pericytes, and analyzed at 4 hours after seeding.
Before seeding, HUVECs and pericytes were fluorescently
labeled with Q tracker 565 and Vybrant Multicolor Cell-
Labeling DiO and DiI (1:500, Molecular Probes, Eugene,
OR), respectively, according to the manufacturer’s
instructions.
Statistical analyses
Student t test and 1-way analysis of variance for multiple
comparisons (for all others) were used to compare the
experimental groups in GraphPad Prism version 5.0 (La
Jolla, CA). A P value < .05 was considered significant.
Experimenters were blinded to the group assignments and
outcome assessments.
Results
EC-specific HIF-1a deletion temporal dependently
affects RIPF by regulating EndMT
To determine whether deletion of EC-HIF1a could directly
regulate RIPF development, EC-HIF1a KO mice were
established by systemic tamoxifen-mediated specific Cre
recombination driven by the vascular endothelial-cadherin
promoter (Fig. 1A). To evaluate the effect of ablative high-
dose radiation similar to SBRT, a single dose of 90 Gy
administered with a 3-mm collimator was delivered to the
left lung of mice. When tamoxifen was administered for 11
days before irradiation, EC-HIF1a deletion did not affect
the progress of RIPF as evaluated by the Ashcroft score and
collagen deposition, or of radiation-induced EndMT
(Fig. 1B and 1C).ly. Lung tissues were obtained from nonirradiated mice and
up). (B, D) Hematoxylin & eosin staining and Masson tri-
d quantification of collagen deposition per field (magnifi-
e staining of CD31 and aSMA in lung tissues at 10 days
Z 5 mm). Quantification of the aSMAþCD31þ/CD31þ area
t score in graphs B and D, error bars indicate SD. For other
< .0001, ns: not significant (1-way ANOVA for multiple
ents. Abbreviations: IR Z irradiation; KO Z knockout;
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Fig. 2. 2-ME inhibits radiation-induced lung fibrosis and EndMT. (A) Representative images of the lungs, hematoxylin &
eosin staining, and Masson trichrome staining in lung tissues from C57BL/6 mice 2 weeks after irradiation (IR), with or
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damage with cell infiltration increased without irradiation,
whereas collagen deposition did not29 (Fig. 1B, upper im-
ages). Therefore, we adjusted the schedule of tamoxifen
treatment and observed that tamoxifen treatment 2 days
before irradiation did not induce vascular damage such as
cell infiltration and collagen deposition (Fig. 1D, upper
images). The change in morphologic patterns of damaged
vessels was easily detected at 10 days after radiation rather
than at 14 days in the fibrotic phase with severe vascular
damage (Fig. 1). At 10 days after radiation, the fibrosis
process began and resulted in collagen deposition to the
parenchymal tissues. Therefore, we examined the early
stage of radiation-induced vascular damage with the fibrotic
phase in EC-HIF1a-deleted mice at 10 days after radiation.
Moreover, EC-HIF1a deletion 2 days before irradiation
inhibited the development of RIPF as estimated by the
Ashcroft score and collagen deposition, also reducing
radiation-induced vascular EndMT (Fig. 1D and 1E). As
tamoxifen is known to have a direct effect on processes
such as angiogenesis,30 we compared the phenotype of WT
mice with and without tamoxifen treatment in nonirradiated
conditions to assess the direct effects of tamoxifen
(Fig. E1A and E1B). The nonirradiated WT phenotype was
not changed by tamoxifen treatment (Fig. 1B and 1D and
Fig. E1A and E1B). Furthermore, in EC-HIF1a KO mice
without tamoxifen treatment, EC-HIF1a could not be
deleted in nonirradiated lungs, and they did not show
vascular damage such as cellular infiltration (Fig. E1A).
Figure E1, parts C and D, shows that HIF-1a was suc-
cessfully knocked out in the EC of irradiated lung tissues
The HIF-1a inhibitor, 2-ME, inhibits RIPF in
ablative high-dose RT
To evaluate whether upregulated EC-Hif1a after RT may
constitute a valid target for inhibiting radiation-induced
vascular damage and RIPF, we next evaluated the effects ofwithout inhibitors (2-ME, amifostine, or pirfenidone). Scoring of
field (magnification, 200) is shown. Scale barZ 100 mm. Mice
pirfenidone, or vehicle, 1 hour before irradiation, and dosing con
were obtained from nonirradiated animals and after focal 90 G
C57BL/6 mice were i.p. or orally (p.o.) administered 2-ME start
Materials and Methods. C57BL/6 mice were administered 2-M
before irradiation, and dosing continued every 2 to 3 days for a to
were injected i.p. (post-treatment) with 2-ME starting 4 days after
5 doses. Lung tissues were obtained from nonirradiated mice and
per group). (B) Representative images of lungs, hematoxylin & eo
schematic of 2-ME treatment strategies, and scoring of fibrosis
(magnification, 200). Scale bar Z 100 mm. (C) Immunofluoresc
Z 20 mm, scale bar of cropped imagesZ 5 mm). Immunofluoresc
Z 50 mm, scale bar of cropped images Z 5 mm). Quantification o
CD31þ as an average of 5 fields (magnification, 100). For the A
other graphs, error bars indicate SEM. )P < .05, yP < .01, zP < .
multiple comparison). Data are representative of 3 independent2-ME on RIPF in ablative high-dose RT. Compared with
normal tissues, morphologic changes in irradiated lung
tissues were observed in the irradiated area at 2 weeks after
90 Gy focal irradiation with a 3-mm collimator (Fig. 2A).
As shown by H&E and trichrome staining, irradiation
significantly induced fibrotic changes and collagen depo-
sition. However, intraperitoneal injection of 2-ME effi-
ciently inhibited RIPF in a dose-dependent manner, as
evidenced by the Ashcroft score and collagen deposition
(Fig. 2A, left). Furthermore, the radio-protective and anti-
fibrotic effects of 2-ME were higher than those of ami-
fostine, a synthetic sulfhydryl compound approved by the
FDA as a radio-protector, and of pirfenidone, which was
recently developed as a pharmacologic treatment for idio-
pathic pulmonary fibrosis31,32 (Fig. 2A, right).
To further validate the pharmacology of 2-ME, we
compared its effects on RIPF when administered intraper-
itoneally on alternative days starting 1 hour before or 4
days after irradiation (Fig. 2B). Posttreatment with 2-ME
also appeared to significantly inhibit the RIPF occurring
at 2 weeks after irradiation, as evidenced by the Ashcroft
score and collagen deposition (Fig. 2B) in the irradiated
lung tissue. These results suggest that 2-ME exerts both
preventive and therapeutic efficacy on RIPF (Fig. 2B). Oral
administration of 2-ME also reduced RIPF significantly
(Fig. 2B). Notably, 2-ME treatment concomitantly inhibited
radiation-induced EndMT at 2 weeks after focal exposure
to high-dose radiation (90 Gy) (Fig. 2C).
HIF-1a and HIF-2a bind to the hypoxia response ele-
ments (HRE)33; endothelial HIF-2 a is well known to regu-
late hypoxic pulmonary hypertension.34 We examined the
effects of 2-ME on endothelial HIF-1a and HIF-2a expres-
sion in RIPF development (Fig. E2B and E2C). Two weeks
after irradiation, both HIF-1a and HIF-2a expression was
significantly upregulated in irradiated lung tissues compared
with that in nonirradiated tissues. Radiation-induced HIF-1a
expression was increased by 3-fold compared with HIF-2a
expression (Fig. E2B). 2-ME effectively inhibitedfibrosis grade and quantification of collagen deposition per
were intraperitoneally (i.p.) injected with 2-ME, amifostine,
tinued every 2 to 3 days for a total of 6 times. Lung tissues
y irradiation (day 14) (n Z 6 animals per group). (B, C)
ing 1 hour before or 4 days after irradiation as described in
E i.p. (pretreatment) or p.o. (pretreatment) starting 1 hour
tal of 6 doses. For the post-treatment group, C57BL/6 mice
irradiation, and dosing continued every 2 days for a total of
after a focal 90 Gy irradiation (day 14) (n Z 5-7 animals
sin staining, and Masson trichrome staining in lung tissues,
grade and quantification of collagen deposition per field
ence staining of CD31 and aSMA in lung tissues (scale bar
ence staining of CD31 and HIF-1a in lung tissues (scale bar
f the aSMAþCD31þ/CD31þ area and the HIF-1aþCD31þ/
shcroft score in graphs A and B, error bars indicate SD. For






















































































































































0 5 days 10 days 20 days (post IR)




















































































NoIR Vehicle 2-ME (60 mg/kg)
IR























































Fig. 3. 2-ME inhibits pericytes integration into endothelial cell (EC) and increases radio-response of spontaneous lung tumors,
showing reduced tumor EndMT. (A) Effect of 2-ME on HUVEC tube formation in the presence and absence of pericytes after
irradiation (IR). Tube numbers per field and fraction of pericytes integrated into EC complexes (200magnification) are given.
Error bars indicate the mean  SD, n Z 4. (B) FDG-PET/CT imaging of non-small cell lung cancers (NSCLCs) in
LSL-KrasG12D;Trp53flox/flox (LSL-KrasG12D;p53 fl/fl ) mice that received 16 Gy thoracic radiation, with or without 2-ME. At 6
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expression (Fig. E2B). Immunoblotting assay also showed
that irradiation at a dose of 10 Gy increased HIF-1a and HIF-
2 expression on ECs by 7.32-fold and 1.70-fold, respectively,
and that 2-ME significantly inhibited HIF-1a and HIF-2a
expression (Fig. E2C). From these results, we cautiously
suggest that 2-ME affects RIPF by inhibiting radiation-
induced HIF-1a expression to a greater extent than
radiation-induced HIF-2a.
To verify whether 2-ME might be suitable as a thera-
peutic agent against RIPF in high-dose radiation therapy
and SBRT, a single toxicity study was also performed with
different doses (60, 150, and 300 mg/kg) of 2-ME intra-
peritoneally administered to mice. Notably, no effect on
body weight was observed (Fig. E2). As shown in Table E1,
the liver, spleen, and lung did not significantly differ after 2
weeks of 2-ME administration at 300 mg/kg. After a single
administration, 2-ME did not produce any toxicity.
2-ME inhibits tumor EndMT and enhances
spontaneous lung tumor radio-response
It was previously reported that targeting tumor EndMT
inhibits tumor vasculature, including abnormal pericyte
recruitment in tumor regrowth after RT.19 This was
revealed using isolated tumor cells from a spontaneous
NSCLC (NSCL-KP tumor) model in which inhalation of a
replication-deficient adenovirus expressing Cre (Ad-Cre)
initiated activation of oncogenic K-RasG12D and deletion of
both copies of a conditional p53 (p53flox) allele by the Cre-
loxP system.14 Based on these reports, we hypothesized
that a pharmacologic approach targeting radiation-induced
tumor EndMT would inhibit tumor vasculature expansion
and consequently inhibit tumor growth and metastasis after
RT. First, in an in vitro assay, we showed that 2-ME
inhibited pericyte integration into irradiated EC com-
plexes in addition to tubule formation (Fig. 3A), which had
been suggested to regulate tumor vasculature with pericyte
recruitment.19 Therefore, we next determined whether 2-
ME might also inhibit tumor endothelial HIF-1a expres-
sion and subsequently tumor EndMT during tumor
regrowth after RT. To evaluate the effect of 2-ME on tumor
radiation response, the tumor response to 16 Gy irradiation
in the thoracic area was assessed using fluorodeoxyglucose-
positron emission tomography (FDG-PET). Tumorweeks following Ad-Cre administration, FDG-PET/CT images w
imaging was repeated 5, 10, and 20 days following irradiation. (C
autologous lung adenocarcinoma from LSL-KrasG12D;p53 fl/fl mi
nodule number per mouse (right) (10magnification) were quantifi
(no IR, nZ 6; IR, nZ 7; IRþ 2-ME, nZ 6). Data are representati
detection of CD31, aSMA, and NG2 (D), and CD31 and HIFa
after irradiation, with or without 2-ME. aSMAþNG2þCD31þ per
magnification) were quantified (scale barZ 20 mm, scale bar of cro
nZ 6.)P< .05, yP< .01, zP< .001, and §P< .0001, ns: not signifi
SUV Z standard FDG uptake value of the tumor.metabolism at 20 days after irradiation (6 weeks after Ad-
Cre infection) was suppressed compared with that of con-
trol tumors. Irradiation combined with 2-ME was markedly
more effective than either treatment alone for suppressing
tumor metabolism (Fig. 3B). Furthermore, H&E staining
confirmed that the treatment combination dramatically
delayed tumor growth compared with that with irradiation
alone (Fig. 3C). These results demonstrated that 2-ME
increased the radio-response of NSCLCs.
As expected, irradiation triggered tumor EndMT with a
concomitant increase in SMAþ NG2þ vessels, whereas
these were inhibited when irradiation was combined with 2-
ME (Fig. 3D). In addition, the upregulated HIF-1aþ vessels
that accompanied tumor EndMT were efficiently reduced
after treatment with 2-ME (Fig. 3E).
2-ME inhibits RIPF in IGRT for single- and
multifocal tumors
As lung tissues bearing tumors are considered to be com-
plex tissues, including aberrant infiltrating immune cells,
vascular cells, and extracellular matrix,35 we hypothesized
that the tumor microenvironment can affect RIPF occur-
rence in antitumor RT. Therefore, as a more clinically
relevant model of RT, we further examined the effect of 2-
ME on RIPF in IGRT for spontaneous murine lung tumors.
To this end, we generated tdTomato; K-RasG12D; p53KO
mice to facilitate the tracking of tumor cells expressing
tdTomato initiated by the application of Adeno-Cre
(Fig. 4A). First, a single-nodule tumor was generated by
intrathoracic application of Adeno-Cre, and then
tdTomatoþ tumors were detected using an in vivo imaging
system (IVIS) (Fig. 4A). Tumor nodules ranged from 100
to 150 mm3 within 3 to 4 weeks.
Furthermore, a beam of 75 Gy was applied to the left
lung tumor using a 5-mm collimator to protect the opposite
lung and spinal cord, as shown in Figure 4B. Computed
tomography (CT) images of the lung were then used to
predict fibrosis or pneumonitis. At 2 or 4 weeks after 75 Gy
focal irradiation, the typical micro-CT manifestations in
RILI were observed including ground-glass opacities and
pulmonary consolidation (Fig. 4C).36 These phenomena
were significantly reduced by oral administration of 2-ME
concomitant with significant tumor growth arrest
compared with that in nonirradiated lungs (Fig. 4C). Inere obtained and the mice were irradiated. FDG-PET/CT
) Representative images of hematoxylin & eosin staining of
ce after Ad-Cre injection and irradiation (left), and average
ed (scale barZ 20 mm). Error bars indicate themean SEM
ve of 2 independent experiments. (D, E) Immunofluorescence
(E) in NSCLCs from LSL-KrasG12D;p53 fl/fl mice 2 months
CD31þ area and HIFaþ CD31þ area per CD31þ area (200
pped imagesZ 5 mm). Error bars indicate the mean SEM,
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Fig. 4. 2-ME inhibits radiation-induced pulmonary fibrosis (RIPF) and delays tumor growth in image guided radiation
therapy for single-nodule non-small cell lung cancer. (A) Schematic diagram of the local lung adenocarcinoma model and
in vivo fluorescence imaging of tdTomato-labeled primary tumors. Left lung of LSL-KrasG12D;Trp53fl/fl;CAG-tdTomato mice
were locally intrathoracically injected with Ad-CRE virus to induce single-nodule primary lung adenocarcinoma. (B) Precise
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combined treatment with 2-ME than that with vehicle
(Fig. 4C).
Trichrome staining showed that 2-ME reduced collagen
deposition on irradiated normal cells (Fig. 4D); moreover,
the population of tomato-positive tumor cells could be
distinguished from normal lung cells (Fig. 4D and 4E). At 4
weeks after RT, EndMT in tomato-normal areas and
tomatoþ tumoral areas that appeared in the irradiated area
were efficiently inhibited by treatment with 2-ME
(Fig. 4E).
To elucidate the effects of 2-ME on RIPF after RT of
multifocal tumors, multi-NSCLC tumor nodules were
generated by intranasal Adeno-Cre application (Fig. 5A),
which involved a beam of 75Gy being applied to the left lung
multitumor nodules using a 5-mm collimator to encompass
the left multitumor volume (Fig. 5B). As a result, 2-ME
markedly reduced RIPF compared with the effects of
vehicle, thereby causing a reduction in ground-glass opaci-
ties and pulmonary consolidation and increased normal lung
volume after IGRT (Fig. 5B). Trichrome staining showed that
2-ME reduced collagen deposition on irradiated normal cells
and the population of tomato-positive tumor cells (Fig. 5C).
EndMTand HIF-1aþ vessels in both the tomato-normal area
and the tomatoþ tumoral areawere also reduced by treatment
with 2-ME (Fig. 5D).Discussion
Here, using an inducible Cre-lox-mediated Hif1a deletion
mouse line, we found that vascular endothelial-specific
HIF-1a deletion shortly, albeit not extensively, before RT
inhibited the progression of RIPF along with reduced
EndMT, as did post-RT administration of the HIF-1a in-
hibitor 2-ME, suggesting targeting post-RT-elevated HIF-
1a as a new mechanism to reduce RIPF. Moreover, IGRT
using primary mouse models of NSCLC showed that
combined treatment of 2-ME with ablative high-dose RT
efficiently inhibited RIPF along with radiation-induced
EndMT while simultaneously increasing radiosensitivity
of both single and multifocal tumors. Collectively, these
results suggested that a negative regulator of HIF-1a-targeted irradiation planning SmART-plan system and dose of the
dose of the target in coronal view, opposite lung dose and spina
dicates the point dose of the irradiation planning system. (C) Mic
fl;CAG-tdTomato mice that received 75 Gy focal irradiation (IR
istration, horizontal (upper), transaxial (middle), and 3D micro-
imals (0, 4 weeks) and after a focal 75 Gy irradiation (0, 2, 4
Representative images of lungs, immunofluorescence staining o
staining (scale bar Z 100 mm). (E) Immunofluorescence staining
bar of cropped images Z 10 mm) in lung tissues from (C). Q
magnification, 200) and the aSMAþCD31þ/CD31þ area as an a
graphs, error bars indicate SEM. )P < .05, yP < .01, ns: not sign
representative of 3 independent experiments.mediated EndMT, such as 2-ME, may serve as a promising
inhibitor of RIPF in radiation therapy.
The role of hypoxia in radiation-induced normal tissue
damage has been previously reported.12 In response to
hypoxia, it is well established that HIF-1a and HIF-2a
regulate angiogenesis via vascular endothelial growth fac-
tor.37 However, the hypoxia-dependent mechanism of HIF
function in radiation-induced normal tissue damage re-
mains unclear. In this study, we found that both HIF-1a and
HIF-2a expression were upregulated in RIPF development
and inhibited by 2-ME treatment. However, the inhibitory
effect of 2-ME on HIF-1a was higher than that on HIF-2a
expression in RIPF. In further study, the role of HIF-2a in
RIPF and the effects of 2-ME on RIPF via inducible HIF-
2a-deleted mice will be investigated.
Tie-2-promotorespecific Hif-1a deletion did not display
protective effects against acute radiation syndrome after
abdominal irradiation.38 Recently, Toullec et al. revealed
that in the acute exposure of the intestine to localized ra-
diation after exteriorization, endothelial HIF-1a-deletion
protects against radiation-induced enteritis, whereas
epithelial HIF-1a-deletion does not.39 Moreover, the re-
ported effects of vascular HIF-1 on normal tissue injury are
contradictory.40-42 In a study conducted by Bryant et al.,
vascular endothelial HIF-1a was revealed to protect against
pulmonary hypertension consequent to chronic hypoxia.41
Recently, Lavigne et al. also reported that in HIF-1a
floxed/VECad-Creþ/ mice, endothelial HIF-1a deletion
reduced acute lung edema and neutrophil infiltration after
lung stereotactic RT, but not long-term damage such as
impaired running performance.43 EndMT during RIPF
development was mainly detected in HIF-1aepositive
vascular ECs of hypoxic regions.12 By using HIF-1a
floxed/VECad-Cre-ERT2þ/ mice, in the present study we
demonstrated that prolonged deletion of endothelial HIF-1a
before irradiation did not protect against RIPF develop-
ment, whereas short-term deletion before RT exhibited an
inhibitory effect by regulating radiation-induced EndMT.
These conflicting results might therefore occur due to the
status of vascular damage consequent to HIF-1a deletion at
specific times before RT. Prolonged deletion of endothelial
HIF-1a increased vascular damage such as cellular infil-
tration without irradiation, which in turn can accelerate
radiation-induced normal tissue damage.main region. Target dose in coronal view, peripheral region
l cord dose with 75 Gy using a 5-mm cone. Each dose in-
ro-CT images of the entire thorax in LSL-KrasG12D;Trp53fl/
), with or without 2-ME. At 4 weeks after Ad-Cre admin-
CT (bottom) images were acquired from nonirradiated an-
weeks). Quantification of normal lung area is shown. (D)
f tdTomato (scale bar Z 200 mm) and Masson trichrome
of aSMA, tdTomato, and CD31 (scale bar Z 50 mm, scale
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Fig. 5. 2-ME inhibits radiation-induced pulmonary fibrosis and tumor growth of multinodule non-small cell lung cancer
after irradiation. (A) LSL-KrasG12D;Trp53fl/fl;CAG-tdTomato mice were intranasally infected with Ad-CRE virus to induce
multinodule primary lung adenocarcinoma. Left lung multitumors were irradiated with 75 Gy using a 5-mm cone. (B) Micro-
CT images of the entire thorax in LSL-KrasG12D;Trp53fl/fl;CAG-tdTomato mice that received 75 Gy irradiation, with or
without 2-ME. At 4 weeks after Ad-Cre administration, horizontal (upper), transaxial (middle), and 3D micro-CT (bottom)
images were acquired from nonirradiated animals (0, 4 weeks) and after 75 Gy irradiation (0, 2, 4 weeks). Quantification of
normal lung area is shown. (C) Representative images of lungs, immunofluorescence staining of tdTomato (scale bar Z 200
mm) and Masson trichrome staining (scale bar Z 100 mm), and (D) immunofluorescence staining of aSMA, tdTomato, and
CD31 (scale bar Z 50 mm, scale bare of cropped images Z 10 mm) in lung tissues from (B). Quantification of collagen
deposition per field (magnification, 200) and the aSMAþCD31þ/CD31þ area as an average of 5 fields (magnification,
100). Error bars indicate SEM. )P < .05, yP < .01 (1-way ANOVA for multiple comparison). Data are representative of 3
independent experiments.
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collagen composition in the interstitial areas at 2 weeks
after 90 Gy-focal irradiation. Previously, it has been re-
ported that extensive collagen with late-stage fibrosis was
deposited at 4 weeks after 90 Gy-focal irradiation. In
particular, we performed a functional evaluation using a
Flexivent system. Inspiratory capacity was decreased
significantly at 2 weeks and 4 weeks; decreased hysteresis,
and increased tissue damping were prominent at 4
weeks.11,25 Therefore, we cautiously suggest that 2-ME
could have beneficial effects several months after expo-
sure, on the late stage of RIPF.
Radiation-pneumonitis (RP) is considered a common
toxicity after SBRTand conventional radiation therapy to the
lung,44 and it can occasionally cause death. In SBRT, plan-
ning target volume (PTV) volume and organ motion were
correlated with RP.45 Radiation-induced EndMT is reported
to occur in the initial step, before the tissue fibrotic phase
during the development of fibrosis.12 Thus, we cautiously
suggest that targeting radiation-induced EndMT may be
effective in inhibiting RP. We will examine the effects of 2-
ME on RP and conventional RT and SBRT in future
studies.Moreover, themodel of normal tissue damage caused
by ablative high-dose RT in this study is useful for counter-
measure development, and 2-ME is suggested to be studied as
a countermeasure in high-dose radiation exposure.
A phenotypic change in EndMT causes vascular dis-
eases, such as tissue fibrosis, which promotes cancer-
associated fibroblasts in cancer. EndMT may also be
accompanied by tumor pericyte coverage46 and cause
tumor resistance to chemotherapy.47,48 The inhibition of
tumor EndMT following RT can suppress lung tumor
regrowth and metastases.19
As a promising EndMT inhibitor, 2-ME enhanced tumor
susceptibility to radiation therapy, with decreased aSMAþ
NG2þ vessel formation. To distinguish the responses of the
tumoral region and nontumoral region, we used sponta-
neous lung tumor models with tracking of tdTomato-
expressing tumor cells. This GEMM may be helpful to
distinguish the responses of normal cells from a single
tumor and multitumor in RIPF development. Additionally,
analysis of the radio-response of NSCLCs using FDG-PET
suggest that 2-ME inhibits tumor glycolysis in combination
with radiation therapy. Targeting HIF-1 and tumor glucose
metabolism has been reported to enhance the efficacy of
radiation therapy.49
Together with the findings of the present study, this sug-
gests that development of strategies to regulate EndMTwill
provide valuable insights for the enhancement of RTefficacy
to reduce RIPF and overcome tumor radio resistance.Conclusions
It was previously revealed that 2-ME, a HIF-1a inhibitor,
efficiently prevents radiation-induced EndMT.12 As such,
both pre- and posttreatment with 2-ME were demonstratedto efficiently inhibit RIPF after ablative focal irradiation,
concomitantly reducing EndMT. In the present study, we
established a preclinical platform combining GEMM and
IGRT to recapitulate human cancer with spontaneous tu-
mors and RT, respectively, for the purpose of evaluating an
RIPF inhibitor in radiation therapy for NSCLC. Specif-
ically, a tumor tracing system using tdTomato;K-
RasG12D;p53KO mice allowed visualization of easily
discernable fibrotic changes between tumoral and normal
regions. Our findings highlight the clinical implications of
2-ME in RT for lung cancer, ultimately revealing that 2-ME
in combination with RT inhibits the development of RIPF
and tumor regrowth in IGRT as shown using single- and
multifocal NSCLC mouse models. Notably, these outcomes
are likely to be clinically meaningful in both palliative and
curative radiation therapies, potentially minimizing normal
tissue complications. However, further studies are encour-
aged to better understand the clinical usefulness of 2-ME in
fractioned RT. Nevertheless, the findings presented herein
suggest that targeting HIF-1a-mediated EndMT might
constitute a viable strategy for lung fibrosis, especially
RIPF. In addition, 2-ME, a suggested regulator of HIF-1a-
mediated EndMT, may be useful as an effective inhibitor of
RIPF in RT.References
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